Accelmed posts 5-fold return in NeuroPace IPO
Last week, US company NeuroPace, Inc. (Nasdaq: NPCE), which is developing a treatment for epilepsy, completed an IPO on Nasdaq. Accelmed Partners, controlled by managing partner Dr. Uri Geiger, had invested $15 million in…